Patients should be warned against interruption or discontinuation of therapy without the physician’s advice. If angina markedly worsens or acute coronary insufficiency develops, metoprolol tartrate tablets USP administration should be reinstated promptly, at least temporarily, and other measures appropriate for the management of unstable angina should be taken. When discontinuing chronically administered metoprolol tartrate tablets USP, particularly in patients with coronary artery disease, the dosage should be gradually reduced over a period of 1 to 2 weeks and the patient should be carefully monitored. Severe exacerbation of angina, myocardial infarction and ventricular arrhythmias have been reported in patients with coronary artery disease following the abrupt discontinuation of therapy with beta-blockers. Ischemic Heart DiseaseDo not abruptly discontinue metoprolol tartrate tablets USP therapy in patients with coronary artery disease.
